Table 2.
Ref. | Groups | n | Age (yr) | Sex (M/F) | Etiology (alcohol/viral/other) | Child-Pugh score or class A/B/C | Follow-up (mo) | Lost to follow-up | Small varices, n | No varices, n |
Andreani et al[11] | Propranolol | 43 | 55.0 ± 1.3 | 27/16 | 33/-/10 | 10/19/13 | NA | 6 | 15 | 0 |
Placebo | 41 | 55.6 ± 1.7 | 23/18 | 33/-/8 | 10/21/10 | NA | 2 | 17 | 0 | |
Conn et al[16] | Propranolol | 51 | 54 ± 9 | 38/13 | 39/-/12 | Mean: 8.0 | 17.1 ± 10.9 | NA | 26 | 0 |
Placebo | 51 | 54 ± 11 | 35/16 | 41/-/10 | Mean: 8.3 | 16.3 ± 12 | NA | 29 | 0 | |
Calés et al[12] | Propranolol | 102 | 52.7 ± 10.4 | 69/33 | 88/-/24 | 6.8 ± 2.1 | NA | 41 | 60 | 42 |
Placebo | 104 | 52.7 ± 11.4 | 68/36 | 81/-/23 | 6.8 ± 2.0 | NA | 32 | 67 | 37 | |
Merkel et al[14] | Nadolol | 83 | 56 ± 9 | 45/38 | 47/34/2 | 6.8 ± 1.6 | 36 ± 18 | 11 | 83 | 0 |
Placebo | 78 | 57 ± 9 | 38/40 | 45/28/5 | 7.1 ± 1.9 | 35 ± 15 | 10 | 78 | 0 | |
Groszmann et al[13] | Timolol | 108 | 46 ± 11 | 70/38 | 26/73/9 | 5.4 ± 0.7 | Median: 52.7 | 0 | 0 | 108 |
Placebo | 105 | 44 ± 11 | 56/49 | 25/69/11 | 5.4 ± 0.8 | Median: 57.9 | 0 | 0 | 105 | |
Sarin et al[15] | Propranolol | 77 | 42 ± 13 | 63/14 | 27/42/8 | 7.4 ± 1.9 | 25 ± 12.6 | 0 | 77 | 0 |
Placebo | 73 | 44 ± 13 | 57/16 | 26/38/9 | 7.7 ± 2.3 | 0 | 73 | 0 |
F: Female; M: Male; NA: Not available. Note: data are expressed as mean ± SD unless otherwise indicated.